Ohm. Take a look at iOncologi when you get a chance. They are creating an mRNA shot that might also increase susceptibility to PD-1, ?"cold to hot" They are the ones CNBC recently profiled.

Also Ganesha previously corrected me that there was no placebo group in our current trials--I must confess I didn't read the trial profile, assuming there was placebo as is standard practice. Are we maybe hoping the open label data will be so good we get conditional approval with these trials with phase 4 confirmation to follow?